Introduction
============

Targeting the androgen receptor (AR) via AR-antagonist therapies is still the mainstay of advanced prostate cancer (PCa) treatments ([@bib1], [@bib2]). AR antagonists, such as enzalutamide, flutamide and bicalutamide, target and competitively bind the AR, to the exclusion of testosterone (or DHT). Additionally AR antagonists may mediate a misfolding of AR helix 12 and cause the AR to become inactive ([@bib3]). In either event, the starvation of prostate cancer cells of testosterone leads to a reduction in tumour cell growth. Often patients undergoing AR-antagonist therapy can become resistant to bicalutamide via many pathways -- involving AR amplification, AR ligand-binding domain (LBD) mutations, cofactor/coregulator changes, and multidrug efflux pumps. Alternatively, in high-grade prostate cancers, tumours may synthesise their own androgens from precursor molecules as a mechanism for escape from such therapies (reviewed in ([@bib4])). Often PCa cells can acquire AR LBD mutations which can change the activity of an antagonist to an agonist, and in some cases patients may acquire PCa that proliferates in the presence of AR antagonists. Such patients may respond better (initially) when AR antagonists are withdrawn ([@bib5], [@bib6]). In addition to all these processes, prostate cancer cells have been shown to produce AR splice variants -- truncated versions of the AR with missing ligand activation domain which remain constitutively active for example, truncated version known as ARv7 ([@bib7]).

The LNCaP cell line represents a human PCa model derived from a patient who relapsed with flutamide therapy ([@bib8]). The LNCaP cell line contains an AR mutation within the LDB (T877A), which allows a greater plethora of ligands to bind and activate the AR, including flutamide. However, the cell line remains sensitive to AR antagonists such as bicalutamide and enzalutamide, but several publications report that prolonged treatment of the LNCaP cell line with AR antagonists or prolonged hormonally starved cells can produce relevant cell lines that mimic clinically acquired AR-antagonists resistance.

The VCaP cell line was established in 1997 from a lumbar vertebral bone metastasis from a metastatic lesion from a patient with hormone refractory prostate cancer. The cell line has been reported to have WT *AR* but overexpresses it at high levels ([@bib9]).

Recently, we generated bicalutamide and enzalutamide-resistant clones of the LNCaP and VCaP cell lines, as tools for screening novel AR-antagonist compounds ([@bib10], [@bib11]). The VCaP^BicR^ ^/^ ^EnzR^-resistant clones showed resistance to both bicalutamide and enzalutamide -- showing cytostatic effects at high doses. However, the LNCaP^BicR^ cell lines showed a proliferative response to bicalutamide, whilst LNCaP/EnzR cells showed a more cytostatic effect at high doses.

In an attempt to discover the potential mechanism of AR-antagonist resistance and to discover if any novel *AR* variants were being expressed or if novel LBD mutations were present, we subjected LNCaP^BicR^ cells to RNA-seq. Here we discuss the finding that although no new coding variant or mutations were seen, we did discover an increase in an *AR* variant, in the 3′UTR region. Here we investigate how the variant conveys extra stability to the *AR* mRNA transcript and may be in part responsible for increased AR mRNA and protein expression in response to AR-antagonist-mediated hormone starvation.

Materials and methods
=====================

Cell culture
------------

LNCaP cells were maintained at 37°C, 5% CO~2~ in RPMI medium with 10% foetal bovine serum (First Link Ltd, Brierley Hill, UK). PC3, VCaP and Du145 cells were maintained in DMEM medium (Sigma) with 10% foetal bovine serum (First Link UK). All media was supplemented with 2 mM [l]{.smallcaps}-glutamine, 100 units/mL penicillin, 100 mg/mL streptomycin (Sigma). For hormone depletion experiments, 72 h before androgen exposure, medium was replaced with 'starvation medium' consisting of phenol red-free RPMI (or DMEM) medium, supplemented with 5% charcoal-stripped foetal bovine serum (First Link UK). All cells were obtained from the ATCC cell bank in 2017, and kept in liquid N~2~ in aliquots thereafter. All cells were used within ten passages of the original stock. RNA-seq of the samples also verified these cell lines in terms of oncogenes and documented mutations.

Treatments
----------

All AR-antagonist compounds were obtained from Sigma, and made up in DMSO stock at 10 mM and kept at −20°C. Actinomycin-D was made up in DMSO at 100 µg/mL, and kept at −20°C. Working solution was 1 µg/mL.

Generation of bicalutamide-resistant cells
------------------------------------------

LNCaP and VCaP cells were grown in increasing doses of bicalutamide or enzalutamide (0--30 µM) for up to 6 weeks at which time cells began to show proliferation. Resistant cell lines were expanded from these and resistant clones grew stably in medium containing 20 µM AR antagonist.

MTT assays
----------

The MTT assay was used as a cell viability assay for the all the cell lines listed using the AR-antagonist compounds. Briefly, cells (5 × 10^4^ cells/mL) were seeded into 96-well plates (200 µL/well), allowed to attach and grow for 24 h and subsequently treated with varying concentrations of AR antagonists (0--100 μM) for 96 h. Optimal seeding densities were premeasured for linear growth over the 96 h. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 5 mg/mL in PBS) was added to a final concentration of 0.5 mg/mL for 4 h at 37°C. After 4 h, purple formazan crystals, formed by mitochondrial reduction of MTT, were solubilized in acidified isopropanol (200 μl/well) and the absorbance was read at 570 nm after 10 min incubation. Percent inhibition of viability was calculated as a % of untreated control and the cytotoxicity/cell growth inhibition was expressed as IC~50~.

AR 3′UTR transfection and luciferase assays
-------------------------------------------

*AR* UTR reporters were a kind gift from Dr Paivi Ostling (Science for Life Laboratory, Sweden). Cells were transfected with *AR*-UTR reporter vectors ([@bib12]), and a constitutive expression *Renilla* (*hRluc*) vector (pGL4.75 Promega) alongside using Lipofectamine 3000 (Life Technologies). 24 h after transfection cells were washed and lysed in reporter lysis buffer (Promega). Lysate was mixed with [d]{.smallcaps}-luciferin substrate (Promega), and then with Renilla substrate (Promega). Light emission measured using the Promega Glomax multi luminometer. Luciferase activity was normalised to *Renilla* (*hRluc*) expression.

RNA extraction and RT-PCR
-------------------------

Total RNA samples were prepared using TRIzol reagent (Sigma) and converted to cDNA using the GoScript™ RT System (Promega).

Q-PCR
-----

Reactions were performed in triplicate on cDNA samples in 96-well optical plates on an ABI Prism StepOne System (ThermoFisher). Reactions consisted of 2 μL cDNA, 7 μL PCR-grade water, 10 μL 2× TaqMan Universal PCR Master Mix (Applied Biosystems), 1 μL TaqMan-specific assay probes (Applied Biosystems) for *PSA*, and *RPL19* or SYBR green primers for *AR*, *AR*-UTR (variants), *β-actin* (*ACTB*) and *GAPDH* (for primer details, see Supplementary Table 2, see section on [supplementary materials](#supp1){ref-type="supplementary-material"} given at the end of this article). Parameters were 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 s and 60°C for 1 min. Data were recorded using Sequence Detector Software (SDS version 2.3; PE Applied Biosystems). Levels were normalised to *GAPDH*, *β-actin* and *RPL19*.

RNA-seq analysis
----------------

PolyA mRNA was isolated from total RNA using the Dynabeads mRNA DIRECT Kit (Life Technologies) and verified using a Bioanalyser-2100 (Agilent). RNA fragment libraries (150--200 bp) were generated using the Ion Total RNA-Seq kit (Life Technologies) and ligated to adapters for cDNA synthesis. cDNA was then amplified using IonXpress RNA-seq barcoded primers (5′) and quantified with a Qubit assay (Life Technologies).

cDNA libraries were clonally amplified by emulsion PCR on Ion Sphere Particles (ISP's) using Ion PI template OT2 200 kit (Life Technologies) on an Ion OneTouch2 system (Life Technologies) as per manufacturer's instructions. The template-positive ISP's were recovered and enriched to remove non-template ISP's on Ion One Touch ES (Life Technologies). The ISPs were processed using the Ion Proton 200 sequencing kit and loaded onto a P1 chip and sequenced on an Ion Proton (Life technologies) using default parameters (single-end, forward sequencing). Base calling, adaptor trimming, barcode deconvolution and alignment was performed on Torrent Suite, version 3.6 (Life Technologies) using the STAR RNA-seq aligner plugin. The Partek Genomic Suite 6.6 software was used for data analysis. The RPKM normalization method for RNA-seq 45 was used followed by a one-way ANOVA test for gene differential expression (from *n* = 4 samples per group). For transcript analysis, we utilised the RNA STAR aligner (or HISAT2 v2.1.0) followed by the Bowtie and TopHat splice aware mapping software (UCSC Galaxy). Finally, Cufflinks (version 2.2.1) and DESeq2 (version 1.12.4 running on R version 3.3.0) were used to build transcript information and visualised in IGV (Integrative Genomics Viewer) software (Broad Institute, University of California, USA).

For online GEO dataset analysis, we used an SRA download tool (UCSC Galaxy), followed by alignment as listed earlier, and analysis via StringTie (v1.3.6).

Serum collection
----------------

Clinical samples were obtained from the Wales Cancer Bank (WCB) in accordance with their ethics and patient consent, following application and approval (WCB application number 15/009). In total 124 samples of serum were used from patients with confirmed prostate cancer. The median patient age was 65 years and the median follow-up period was 4 years. Patient serum was collected at the point of first diagnosis based on pathological Gleason grade from biopsy, prior to any treatment. No TNM data were available. In addition we collected serum samples from normal healthy male volunteers, with an age range of 20--55 years (ethics number SMREG ref:13.69). 50 µL of serum was used and RNA was extracted using 150 µL of TRIzol LS.

Results
=======

AR mRNA transcript and protein expression are increased with acquired AR-antagonist resistance
----------------------------------------------------------------------------------------------

We set out to analyse and study the mechanism of action of acquired AR-antagonists resistance in prostate cancer cell models. The baseline sensitivity of LNCaP and VCaP cells to bicalutamide and enzalutamide was measured using the MTT assay for cell viability. Treating cells for 96 h in increasing doses of bicalutamide showed an IC~50~ of 3 µM for LNCaP cells and 2.5 µM for VCaP cells. Enzalutamide gave IC~50~ values of 2 and 2.3 µM respectively. After continual culture and growth in 20 µM bicalutamide or enzalutamide for 6 weeks approx., these cells began to grow and proliferate as normal, and cell lines were expanded -- henceforth labelled LNCaP^BicR^ ^/^ ^EnzR^ and VCaP^BicR^ ^/^ ^EnzR^. A further MTT analysis for the IC~50~ revealed that LNCaP^BicR^ cells now proliferated in bicalutamide reaching maximal growth at approx. 20 µM ([Fig. 1A](#fig1){ref-type="fig"}). Enzalutamide still showed some activity in LNCaP^EnzR^ cells, but the IC~50~ was now 15 µM (approx.) ([Fig. 1A](#fig1){ref-type="fig"}). In VCaP-resistant cell lines, both bicalutamide and enzalutamide failed to give an IC~50~ dose, but no dose-responsive proliferation was observed ([Fig. 1B](#fig1){ref-type="fig"}).Figure 1AR transcript expression is increased with acquired AR-antagonists resistance. (A) MTT cytotoxicity assays of LNCaP, LNCaP^BicR^ and LNCaP^EnzR^ cells treated with increasing concentrations of either bicalutamide (left hand side) and enzalutamide (right hand side), at 0--100 µM for 96 h. (B) MTT cytotoxicity assays of VCaP, VCaP^BicR^ and VCaP^EnzR^ cells treated with increasing concentrations of either bicalutamide (left hand side) and enzalutamide (right hand side), at 0--100 µM for 96 h. (C) qPCR analysis of AR and PSA expression levels in four prostate cancer cell lines, as indicated. (D) qPCR analysis of AR expression levels in parental and resistant prostate cancer cell lines as indicated. Data represent the mean and [s.e.]{.smallcaps} from three independent replicates. Data are normalised to housekeeping genes GAPDH, RPL19 and β-actin. (E) Western blot for AR levels from LNCaP and LNCaP^/Bic/Enz^ cells, normalised to β-actin. Statistical analysis \* (*P* = 0.05), \*\* (*P* = 0.01) from a *t*-test.

Analysis of *AR* and prostate-specific antigen (*PSA*) expression in these cell lines confirmed that VCaP and LNCaP were indeed *AR* ^+ve^ when compared to PC3 and Du145 -- cell lines known to be androgen receptor negative ([Fig. 1C](#fig1){ref-type="fig"}). When we compared parental and resistant cell lines we observed that *AR* expression was increased two-fold in the resistant cell lines ([Fig. 1D](#fig1){ref-type="fig"}) -- although the levels of AR transcripts was much higher in VCaP cells (×100-fold). We PCR-amplified and sequenced the AR LBD domain from these cell lines and did not observe any AR mutations apart from T877A, carried by the LNCaP cell line. Protein levels for AR also increased in the resistant LNCaP cell lines by 1.3-fold ([Fig. 1E](#fig1){ref-type="fig"}).

AR transcripts differ in the 3′UTR region in LNCaP with acquired bicalutamide resistance
----------------------------------------------------------------------------------------

We then analysed the changes in gene expression in the LNCaP vs LNCaP^BicR^ cell lines by RNA-seq. When analysing the *AR* transcripts we did not observe any *AR*-coding region splice variants for example, ARv7, however, we did observe that the 3′UTR region of some *AR* transcripts showed an anomaly. Data are available at NCBI BioProjects accession PRJNA578661 (<https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA578661>).

In the parental LNCaP cells, three distinct *AR* transcripts were identified. Two were complete matches of known transcripts (according to RefGene gene model) and one was a potentially novel transcript. However, in the LNCaP^BicR^ cell line five distinct *AR* transcripts were identified, two of which were complete matches of known transcripts and three were potentially novel transcripts. [Figure 2A](#fig2){ref-type="fig"} showed the analysis schematic from IGV software, showing the Cuffmerge data output. [Figure 2B](#fig2){ref-type="fig"} showed a detailed schematic of the 3′UTR region of *AR*. The novel transcripts had a missing 3 kb region in the UTR sequence, from bases 1795 to 4832 of the UTR sequence. The coordinates are counted from +1 after the stop site in the *AR* mRNA sequence (Refseq: NM_000044) (Supplementary Results 'AR mRNA UTR with primers'). The missing region corresponds to ChrX: position 66,945,478--66,948,515 (GRCh37/hg19 assembly). Additionally, we saw another transcript with a slightly larger missing region from bases 1795 to 4961 ([Fig. 2B](#fig2){ref-type="fig"}). The novel transcript will be henceforth referred to as *AR* ^3.7kb-UTR^, as opposed to *AR* ^6.7kbUTR^, for the normal full-length AR transcript.Figure 2AR transcripts differ in the 3′UTR region with acquired AR-antagonists resistance. (A) IGV screenshot of the AR transcripts detected in RNAseq samples from LNCaP and LNCaP^BicR^ cells. Upper panel indicated the genomic location of the AR intron and exon regions as well as the 5′ and 3′ UTR regions. (B) Schematic diagram of the full 3′ UTR region of AR (6.7 kb), with the missing 3 kb region indicated as a hatched box, and missing 3.1 kb regions (lighter hatched box). The numbers represent the bases in the UTR region at which the missing region are spanned by RNAseq reads. (C) Analysis results from the Spliceport splice analysis online tool. Left hand side indicates bases scoring highly as splice donor regions and right hand side shows bases scoring highly as splice acceptor regions.

3′UTR deletion correlates with splice sites
-------------------------------------------

From the IGV analysis, reads mapping to the 3′UTR spanned the missing 3 kb region, indicating that a splicing or editing event was responsible. Therefore, we analysed the 3′UTR region of the *AR* mRNA via various online resources for splice site analysis. Utilising Spliceport (<http://spliceport.cbcb.umd.edu/SplicingAnalyser2.html>), NetGene2 (<http://www.cbs.dtu.dk/services/NetGene2/>) and RegRNA (<http://regrna2.mbc.nctu.edu.tw/detection.html>) analysis software we found that the bases 1795 and 4832 (and 4961) were predicted splice donor and acceptor regions respectively with the highest confidence value or free energy score. [Figure 2B](#fig2){ref-type="fig"} shows a schematic of the base numbers and deleted region of the 3′UTR of AR. [Figure 2C](#fig2){ref-type="fig"} shows the output from SplicePort for both donor and acceptor predicted sites. We did not detect the novel spliced region in genomic DNA from LNCaP cells, again indicating a post-transcriptional modification.

Spliced AR 3′UTR variant increases due to hormonal starvation or AR-antagonist treatment
----------------------------------------------------------------------------------------

Utilising primers specific for various regions across the UTR ([Fig. 3A](#fig3){ref-type="fig"}), we analysed if the shorter UTR transcript could be detected by PCR. Utilising primers C&D for the long UTR variant and B&E for the shorter UTR variant ([Fig. 3A](#fig3){ref-type="fig"}), we carried out qPCR on the cell lines. The C&D primer set amplifies a region present only in the complete full-length *AR* 3′UTR. The B&E primer set only amplifies the *AR* 3′UTR across a small region (200 bp) of the shorter spliced variant.Figure 3AR 3′UTR variant increases due to hormonal starvation or AR-antagonists treatment. (A) Schematic diagram indicating the binding location of qPCR primer sets used for detecting either a portion of the 6.7 kb 3′UTR of AR (upper panel) or the novel shorter AR 3 kb transcript (lower panel). Numbers represent base locations in the 3′UTR. (B) qPCR analysis of the AR UTR utilising the indicated primers sets in parental LNCaP or VCaP cells. (C) qPCR analysis of AR^6.7kb-UTR^ variant and AR^3.7kb-UTR^ variant in parental and resistant LNCaP and VCaP clones. (D) qPCR analysis of PSA (upper panel) and AR^3.7kb-UTR^ (lower panel) in LNCaP cells grown in starvation medium for 72 h. (E) Western blot for AR protein levels in hormonally starved LNCaP cells for 0--96 h. Normalised to β-actin, with associated densitometry underneath. (F) qPCR analysis of PSA (upper panel) and AR^3.7kb-UTR^ variant (lower panel) in LNCaP cells treated with bicalutamide (10 µM) for 6 days. Data represent the mean and [s.e.]{.smallcaps} from three independent replicates. Data are normalised to housekeeping genes GAPDH, RPL19 and β-actin. Statistical analysis \* (*P* = 0.05), \*\* (*P* = 0.01) from a *t*-test.

Parental VCaP cells showed a 15-fold increase over LNCaP in *AR*-UTR expression ([Fig. 3B](#fig3){ref-type="fig"}). However, interestingly, parental VCaP cells also showed a four-fold increase in the novel shorter UTR variant than LNCaP cells ([Fig. 3B](#fig3){ref-type="fig"}). Further, we then analysed the levels of the normal UTR (primers C&D), and UTR variant (*AR* ^3.7kb-UTR^ - primers B&E) in the resistant cell lines compared to the parental cell lines. This also showed increased expression of the shorter variant in all resistant cell lines ([Fig. 3C](#fig3){ref-type="fig"}), compared to their parental cells.

We then went on to study if the increase in levels of the 3′UTR variants in the parental cells changed rapidly following either hormone starvation or AR-antagonist treatment, or whether the *AR* variant was a product of a longer term adaptation. When LNCaP cells were hormonally starved for 72 h we saw a strong reduction in the levels of the androgen-inducible gene, *PSA*, as expected ([Fig. 3D](#fig3){ref-type="fig"} upper panel). Also, as expected, when starved, LNCaP cells upregulated their levels of *AR* mRNA, therefore, the *AR*-coding region and the normal UTR levels showed an increase of around 6--8 fold (Supplementary Fig. 1). However, the shorter UTR variant could be detected at approx. 20 times the level found in parental cells ([Fig. 3D](#fig3){ref-type="fig"} lower panel). Hormonal starvation for 96 h also increased the level of AR protein by wo-fold ([Fig. 3E](#fig3){ref-type="fig"}). When the parental LNCaP cells were treated with 20 µM bicalutamide for up to 6 days, we observed a decrease in PSA, as expected, but an increase in shorter UTR variant, which increased over time ([Fig. 3F](#fig3){ref-type="fig"}).

The spliced AR 3′UTR variant is more stable in cells with acquired AR-antagonist resistance
-------------------------------------------------------------------------------------------

To monitor if the shorter *AR* UTR variant conferred an advantage to the stability of the *AR* mRNA strand we treated parental and AR-antagonist-resistant cells with actinomycin-D to halt RNA transcription. Total RNA was then extracted from cells at various timepoints. In LNCaP cells actinomycin-D significantly reduced expression of all transcripts over 24 h. The levels of *GAPDH*, *β-actin* and *AR* (coding region), *AR* ^6.7kb-UTR^ did not show any significant differences between the cell lines. However, in the resistant cells the residual levels of *AR* ^3.7kb-UTR^ transcript showed an increased level compared to the parental cell lines at 10 h ([Fig. 4A](#fig4){ref-type="fig"}), but was similarly reduced at 24 h. Similar results were seen in VCaP cells, but to a reduced level (Supplementary Fig. 2).Figure 4Spliced AR 3′UTR variant is more stable in cells with acquired AR-antagonists resistance. (A) qPCR analysis of GAPDH, β-actin, AR^3.7kb-UTR^ variant and AR^6.7kb-UTR^ variant from LNCaP or LNCaP^BicR^ cells treated with actinomycin D (1 µg/mL) for 0--24 h. Data represent the mean and [s.e.]{.smallcaps} from three independent replicates. Data are normalised to housekeeping genes GAPDH, RPL19 and β-actin, and then expressed as a % of expression at time 0. (B) Upper panel -- schematic diagram of the location of the Luciferase-AR UTR reporter fusion constructs in the 6.7 kb region. Lower panel -- luciferase activity of the reporter constructs in LNCaP or LNCaPBicR cells transfected with the firefly luciferase reporters and a constitutive renilla luciferase reporter. Data are expressed as firefly luciferase/Renilla luciferase. Statistical analysis \* (*P* = 0.05), \*\* (*P* = 0.01) from a *t*-test.

We then tested the relative stability of different regions of the *AR* UTR using luciferase reporter constructs. Using seven AR UTR overlapping constructs ([@bib12]) of approximately 1 kb each, were transfected into LNCaP or LNCaP^BicR^ cells for 24 h, and measured luciferase activity over a constitutively expressed Renilla luciferase. Regions 1, 2, 3, 6 and 7 showed increased stability in the LNCaP^BicR^ cells, but regions 4 and 5 which lie within the spliced region of the UTR showed a reduced stability ([Fig. 4B](#fig4){ref-type="fig"}).

The 3′UTR variant is present in online GEO datasets including LNCaP-abl cells, immortalised prostate epithelial cells and in patient samples prior to AR-antagonist therapy
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Both the LNCaP and VCaP cell lines showed low levels of the *AR* UTR variant before the treatment with AR antagonist, but these cell lines represented cells taken from patients with advanced prostate cancer who had been treated with various endocrine therapies for example, flutamide (and/or other treatments). We, therefore, analysed several online datasets from the GEO database for the presence of the 3′UTR variant. In all studies analysed, the 3′UTR missing region was seen at some levels, albeit very low. Using online data from Olsen *et al*., GSE71797 ([@bib13]), in *hTert* immortalised benign prostate epithelial cells we detected the presence of the transcript in some samples but not all (Supplementary Fig. 3A). Additionally, using data from Rajan *et al*. (GSE48403) ([@bib14]), we again found the presence of the shorter *AR* UTR variant. The 3′UTR variant was seen to be elevated in prostate cancer patients post AR-antagonists therapy, but due to low sample numbers (*n* = 6), the data did not reach significance. Data are given in Supplementary Fig. 3B.

The *AR* UTR was also detected and was increased (*P* = 0.03) in a study by Knuuttila *et al*. (GSE95413) in orthotopically grown castration resistant VCaP xenografts treated with enzalutamide (Supplementary Fig. 4A). In a study by Shah *et al*. (GSE81796) using C4-2 cells (CRPC) the *AR* ^3.7kb-UTR^ was present and was increased by enzalutamide treatment (Supplementary Fig. 4B). And in a study by Coleman *et al*. (GSE87153), the *AR* ^3.7kb-UTR^ was seen to be increased in the LNCaP-derived MR49F cell line -- grown in castrated mice and enzalutamide treated (Supplementary Fig. 4C). The variant was present in V16D cell line (LNCaP derived, castration resistant), but was not further elevated with enzalutamide. This missing region in the *AR* UTR was also observed in a study by Kohli *et al*. (GSE70380), in samples derived from metastatic deposits from a patient with disease progression whilst on androgen deprivation therapy (Supplementary Fig. 4D).

The LNCaP-abl cell line represents LNCaP cells grown in androgen-depleted medium for over 80 passages, and mimics castrate-resistant prostate cancer. A GEO dataset (GSE114708) utilising the LNCaP-abl cell line ([@bib15]) showed the presence of the AR^3.7kb-UTR^ variant (Supplementary Fig. 4E).

The AR 3′UTR variant is detectable in prostate cancer patient serum
-------------------------------------------------------------------

Since prostate cancer cells and/or prostate cancer cellular DNA/RNA may circulate in the serum of prostate cancer patients, we evaluated whether the novel variant could be detected in their sera. We extracted total RNA from prostate cancer patients' sera, collected from the Wales Cancer Bank (*n* = 124) ranging from Gleason grade 6--10, with associated PSA values. Additionally, serum was collected from apparently healthy male volunteers (*n* = 8). These were determined by clinical pathologists at the Heath Hospital Cardiff, UK. RNA was isolated and qPCR performed, for *AR* (coding region), *AR* ^6.7kb-UTR^ (primers C&D), and for the AR^3.7kb-UTR^ (primers B&E), along with *GAPDH*, *β-actin* (*ACTB*) and *RPL19*. Patient data and numbers can be seen in Supplementary Table 1.

When analysed according to Gleason grade, we found a positive correlation with PSA as expected, but additionally we saw a positive correlation with increasing grade and the quantity of *AR* ^3.7kb-UTR^ variant in the serum ([Fig. 5A](#fig5){ref-type="fig"} and [B](#fig5){ref-type="fig"}), and statistically significant differences between Gleason grade 6 and 9 (*P* ≤ 0.05). No correlation was seen between the levels of *AR*-coding region and Gleason grade; however, a positive correlation with grade was also seen for the full-length *AR* ^6.7kb-UTR^ ([Fig. 5C](#fig5){ref-type="fig"} and [D](#fig5){ref-type="fig"}).Figure 5Spliced AR 3′UTR variant is detectable in prostate cancer patient serum. (A) Serum PSA measurements from the prostate cancer patient cohort -- data from the Wales Cancer Bank. Data are separated according to Gleason grade 6--10, assigned to each patient at pathological diagnosis. (B) qPCR analysis of the AR^3.7kb-UTR^ variant from RNA extracted from patient serum samples. (C) qPCR analysis of the AR-coding region from RNA extracted from patient serum samples. (D) qPCR analysis of the AR^6.7kb-UTR^ variant from RNA extracted from patient serum samples. Data represent the mean and [s.e.]{.smallcaps} from three independent measurements. Data are normalised to housekeeping genes GAPDH, RPL19 and β-actin. Statistical analysis \* (*P* = 0.05), \*\* (*P* = 0.01) from a one-way ANOVA test (Kruskal--Wallis test).

When analysed for patient follow-up and survival, both PSA and AR^3.7kb-UTR^ were elevated in the deceased group (*P* ≤ 0.05 and *P* ≤ 0.02) respectively. However, due to very small numbers we treat these results with caution. AR^6.7kb-UTR^ and AR-coding region levels did not correlate with survival.

Discussion
==========

During prostate cancer treatment AR antagonists are often used to reduce tumour growth and prolong life. Initially, AR antagonists are effective but frequently these become ineffective and patients relapse with prostate cancer which is resistant to further AR-antagonist treatment. Additionally, AR antagonists may bind and activate the AR causing a stimulatory effect. In instances such as these, prostate cancer patients may benefit from AR-antagonist withdrawal. We set out to investigate the mechanism behind acquired resistance to AR antagonist in prostate cancer cells by generating cells resistant to the two most clinically relevant AR antagonists, namely bicalutamide and enzalutamide.

For LNCaP and VCaP cells, the acquisition of AR-antagonist resistance was established at 20 µM, whereas at 30 µM no growth or very slow cell growth was observed. However, when these resistant cells were then exposed to a range of drug concentrations 0--100 µM we saw different effects dependent on the drug and cell line. VCaP showed resistance to enzalutamide and bicalutamide with no apparent cell killing up to 50--100 mM. LNCaP showed similar properties with enzalutamide. However, LNCaP cells showed a proliferation response with bicalutamide, peaking at 20 µM. This effect is probably due to the steric fit of bicalutamide in the mutant AR ligand-binding domain (T877A) carried by the LNCaP cell line causing a more promiscuous ligand binding. This may also mimic the clinical situation where patients sometimes respond better -- albeit briefly -- when AR antagonists are removed.

When analysing *AR* mRNA levels in these resistant cells, we found expression to be higher at the mRNA and protein levels. The increased expression of *AR* has been previously reported in cells either starved of hormone or inhibited by AR antagonists. VCaP cells show a much higher baseline expression of *AR* and has been reported previously, but even in these cells *AR* expression was still higher in the resistant clones.

When we analysed the *AR* by RNA-seq we did not discover any new or additional mutations in any of these cells lines, neither did we find any novel *AR* coding variants for example, ARv7. However, the RNA-seq and associated Cufflinks analysis did reveal an increase in transcript number and variation. Three isoforms were seen in parental LNCaP cells. The first being *AR* variant 1 (refseq: NM_000044) and the other being *AR* variant 2 (refseq: NM_001011546), which are previously identified variants. Variant 2 has an alternate start codon in the 5′ region, with an encoded isoform (variant 2) which has a distinct and shorter N-terminus than isoform 1. However, even in these parental cells another isoform was seen with a shorter 5′ UTR sequence and a missing 3 kb region from the 3′UTR. In the LNCaP^BicR^ cell line five transcripts were seen -- the three variants seen previously in the parental cell lines and two more variants which were the *AR* variant 2 but with a missing 3 kb region in the 3′UTR and an alternate variant 1 with a missing slightly larger 3.1 kb region.

Since RNAseq reads spanned this area and were aligned and mapped as genuine reads to the *AR* gene, we had to surmise that the missing 3--3.1 kb were caused by 'splicing' or 'stitching' events. Splice site analysis matched up precisely with donor and acceptor sites on several Web-based platforms. The novel variant region could not be PCR amplified from genomic DNA, also indicating a post-transcriptional splicing event.

Although *AR* coding and *AR* UTR levels were elevated in AR-antagonists-resistant cells, PCR analysis confirmed that the missing UTR variant elevated in increasing amounts, indicating that additional *AR* transcripts with the missing region were present in these cells. Even though the high levels of *AR* ^3.7kb-UTR^ were seen in fully resistant cells, we saw that the adaptive response was rapid, being detectable after 24 h of AR-antagonist treatment and after 6 days of hormone starvation.

Additionally, to test whether the *AR* 'splicing' event was unique to AR pathway inhibition or was a more general stress response, we subjected LNCaP cells to a variety of cellular stresses including hypoxia (mimicked by CoCl~2~), DNA damaging stress (by doxorubicin, cisplatin and paclitaxel) and environmental stress such as oxygen radicals (by H~2~O~2~) and extracellular low pH. We observed that both *AR* variants (3.7 and 6.7 kb UTRs) were upregulated in response to environmental stresses for example, oxygen or pH, but were not significantly altered in response to DNA-damaging agents (Supplementary Fig. 5). All stress treatments reduced cellular proliferation as measured by the expression of the *MCM5* DNA replication gene. Oxygen level changes and low pH are significant factors within tumours, and may together with AR antagonism, play a role in prostate cancer. The 'splicing' events observed here may be part of a more generic stress-induced novel or aberrant splicing pathway.

We hypothesised that the *AR* variant was a result of an adaptive response to lack of androgen where the AR mRNA levels increased, and as is the case for alternative 'splicing', the mRNA strand itself may have an altered stability. Splicing of the coding region of the *AR* has been studied extensively, but UTR variants have not ([@bib7], [@bib16]). For example if the shorter UTR variant was more stable, then this would give the *AR* mRNA a longer half-life, and a higher expression which would give cells a survival advantage. We tested this hypothesis using actinomycin-D to stop cellular transcription of all transcripts and measured the half-life of the remaining transcripts. 24 h of actinomycin treatment reduced all transcripts measured including *GAPDH*, *β-actin* (*ACTB*), *AR* ^6.7kb-UTR^ and *AR* ^3.7kb-UTR^. However, the *AR* ^3.7kb-UTR^ showed a higher level and reduced rate of degradation. Additional analysis using *AR* UTR reporters fused to luciferase showed that two regions (4 and 5) showed a reduced activity/stability in the LNCaP^BicR^ cell line, whereas all other regions showed an increased activity. Regions 4 and 5 were in the missing 3 kb region of the novel transcripts. Taken together, we hypothesise that in the adaptation to AR-antagonist resistance the 3 kb RNA region missing in *AR* ^3.7kb-UTR^ may be detrimental for stability of the mRNA strand and may be spliced out to increase stability as a survival advantage for the cancer cells. Although a hypothetical explanation at this stage, we would suggest that this splicing or stitching of the UTR sequence may be a mechanism to avoid or circumvent microRNA or noncoding RNA downregulation of the AR strand. miR analysis software indicated at least 40 potential binding sites in the 3 kb were missing from the AR^3.7kb-UTR^ mRNA strand. For example, if miRNA upregulation was a part of the adaptive AR-antagonist resistance response, then the shortening of the UTR would lessen the chance of *AR* itself being targeted by these miRs. Studies by Ostling *et al*. ([@bib12]) found several active miRNAs which target the 3′UTR of *AR* in the deleted region for example, miR-185, miR-371-3p and miR-135. miR-185 has been shown to downregulate *AR* levels and is itself downregulated in prostate cancer samples ([@bib17], [@bib18]).

Splicing dysregulation has been hypothesised to be associated with cancer and survival mechanisms for example, in PI3kinase/Akt pathways ([@bib19], [@bib20]). 3′UTR splicing events have been found for other genes and is associated with transcript stability ([@bib21], [@bib22], [@bib23], [@bib24]). Often cells utilise alternative cleavage and polyadenylation sites to reduce UTR length and increase mRNA stability ([@bib25]), but in the enzalutamide-resistant cells studied here, although the UTR length is indeed shortened the terminal polyadenylation site is unchanged. This would again imply a novel mRNA 'splicing' and editing event has occurred for the *AR*.

The *AR* ^3.7kb-UTR^ variant was present in the parental LNCaP and VCaP cell lines, but was more prominent in the resistant cells. We then looked at several online GEO dataset to determine if the variant was common or cancer specific. In immortalised (*hTERT*) prostate epithelial cells and in epithelial cells undergoing mesenchymal transition, the variant was present but at very low levels; however, in cancer samples and cancer samples from AR-antagonist-resistant refractory patients we found the levels to be higher, with even higher levels in refractory patients -- although not significant due to low numbers (*P* = 0.3). Therefore, the variant may be a naturally occurring transcript present at low levels, which is stabilised or upregulated at times of cellular stress.

Patients' plasma and serum have been used in the other studies to measure circulating *AR* levels ([@bib26], [@bib27]). In prostate cancer patients' sera, we tested whether the *AR* variant could be detected, as well as the normal *AR* UTR and the *AR*-coding region. Additionally, we compared the patient Gleason grade and PSA levels as indicators of disease. All three *AR* regions were detectable, but it was only the UTR regions that correlated with grade across the patients' samples, and showed significant differences between grades 6 and 9 and 10. Additionally, both PSA and *AR* ^3.7kb-UTR^ showed a significantly higher level in those patients who had died of prostate cancer in the interim follow-up. This was a surprising finding as numbers were low, but no significant correlation could be seen between PSA and *AR* ^3.7kb-UTR^. To our knowledge, these patients were naive to any endocrine treatment protocols, therefore taken together with the online GEO datasets, the appearance of the variant is not caused by AR-antagonist treatments but is upregulated by it. Unfortunately, follow-up data on how patients went on to respond to AR-antagonist therapies were unavailable at the time of this study. Previously, the detection of AR-v7 in whole blood did not predict effectiveness of AR-antagonist for castration-resistant prostate cancer ([@bib27]).

In conclusion, we report that an *AR* ^3.7kb-UTR^ variant levels increase in prostate cancer cells which have acquired resistance to bicalutamide/enzalutamide or indeed shorter-term hormonal starvation. This variant is present at low levels in most cells studied, but the levels are increased in the resistant cells, and the novel variant may be associated with a splicing event. We hypothesise that this variant increases *AR* mRNA stability, thus may increase protein levels and may provide prostate cancer cells a survival advantage.
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###### Supplemental figure 1. Q-PCR analysis of A, AR UTR and B, AR coding region in LNCaP cells grown in stavation medium for 72 hours.

###### Supplemental Figure 2. Q-PCRanalysisofGAPDH,AR3.7kb-UTRandAR6.7kb-UTRfromVCaPorVCaPBicRcellstreatedwithactinomycin-D(1ug/ml)for0-24hours.DatarepresentsthemeanandSEfromthreereplicates.DataisnormalisedtothehousekeepinggenesGAPDH,RPL19,andb-actin,andthenexpressedasa%expressionattime=0.

###### Supplemental figure 3

###### Supplemental figure 4. A,BoxplotshowingtheanalysisoftheARDUTRvariant(inRPKM)fromVCaPxenograftstreatedwithenzalutamide.B,GraphshowinganalysisresultsofARDUTR(RPKM)fromC4-2cellstreatedwithenzalutamide.C,GraphshowinganalysisresultsofARDUTR(RPKM)fromtheMR49Fcellline--grownincastratedmiceandenzalutamidetreated.D,ScreenshotfromCuffmergedataanalysisfrommetastaticdepositsofapatientswithdiseaseprogression.E,ScreenshotfromCuffmergedataanalysisfromLNCaP-ablcells.

###### Supplemental Figure 5. Q-PCRanalysisofLNCaPcellstreatedwithvariousconditionsincludinghypoxiamimicCoCl2(100mM),HCl(10mM),Paclitaxel(1nM),Doxorubicin(1mM),Cisplatin(3mM),H2O2(0.1mM)for24hours.DataisnormalisedtoGAPDH,b-actinandRPL19.

###### AR mRNA full UTR sequence

###### Supplemental Table 1. Numbers and Gleason grades of prostate cancer patient serum samples.

###### Supplemental table 2
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